000661 长春高新
已收盘 11-22 15:00:00
资讯
新帖
简况
国金证券：给予长春高新买入评级
证券之星 · 11-21 14:10
国金证券：给予长春高新买入评级
《股市简讯》中国长春高新一度劲扬5.6%，拟以3-5亿元回购公司股份
路透中文 · 11-18
《股市简讯》中国长春高新一度劲扬5.6%，拟以3-5亿元回购公司股份
长春高新最新公告：拟3亿元-5亿元回购股份
证券之星 · 11-15
长春高新最新公告：拟3亿元-5亿元回购股份
长春高新(000661.SZ)拟回购3亿元至5亿元公司股份 已获3.5亿元回购贷款承诺
智通财经 · 11-15
长春高新(000661.SZ)拟回购3亿元至5亿元公司股份 已获3.5亿元回购贷款承诺
长春高新：拟3亿元-5亿元回购股份
美港电讯 · 11-15
长春高新：拟3亿元-5亿元回购股份
长春高新三季报“变脸”：生长激素市场增长放缓，多领域子公司业绩承压
市场资讯 · 11-12
长春高新三季报“变脸”：生长激素市场增长放缓，多领域子公司业绩承压
长春高新最新公告：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获得批准
证券之星 · 11-05
长春高新最新公告：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获得批准
长春高新(000661.SZ)：聚乙二醇重组人生长激素注射液新适应症获批
智通财经 · 11-05
长春高新(000661.SZ)：聚乙二醇重组人生长激素注射液新适应症获批
长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准
美港电讯 · 11-05
长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准
国泰大健康风格漂移引质疑：基金经理徐治彪曾高位买入长春高新和老百姓
市场资讯 · 11-04
国泰大健康风格漂移引质疑：基金经理徐治彪曾高位买入长春高新和老百姓
【机构调研记录】鑫元基金调研长春高新、澳华内镜等6只个股（附名单）
证券之星 · 10-29
【机构调研记录】鑫元基金调研长春高新、澳华内镜等6只个股（附名单）
【机构调研记录】诺安基金调研博腾股份、长春高新等10只个股（附名单）
证券之星 · 10-29
【机构调研记录】诺安基金调研博腾股份、长春高新等10只个股（附名单）
【机构调研记录】泰信基金调研长春高新、龙迅股份等7只个股（附名单）
证券之星 · 10-29
【机构调研记录】泰信基金调研长春高新、龙迅股份等7只个股（附名单）
长春高新：会积极关注并购重组等多种工具方式 提升上市公司投资价值
美港电讯 · 10-28
长春高新：会积极关注并购重组等多种工具方式 提升上市公司投资价值
长春高新：10月27日接受机构调研，北京成泉资本、东方财富等多家机构参与
证券之星 · 10-28
长春高新：10月27日接受机构调研，北京成泉资本、东方财富等多家机构参与
10月28日长春高新涨7.55%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 10-28
10月28日长春高新涨7.55%，招商国证生物医药指数(LOF)C基金重仓该股
长春高新涨7.55%，国金证券二个月前给出“买入”评级
证券之星 · 10-28
长春高新涨7.55%，国金证券二个月前给出“买入”评级
中国银河：给予长春高新买入评级
证券之星 · 10-27
中国银河：给予长春高新买入评级
子公司金赛药业、百克生物业绩下滑，长春高新前三季度净利降两成
新京报网 · 10-26
子公司金赛药业、百克生物业绩下滑，长春高新前三季度净利降两成
图解长春高新三季报：第三季度单季净利润同比减26.37%
证券之星 · 10-26
图解长春高新三季报：第三季度单季净利润同比减26.37%
暂无数据
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务为生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品为聚乙二醇重组人生长激素注射液、重组人生长激素、注射用重组人促卵泡激素、冻干水痘减毒活疫苗、人用狂犬病疫苗、血栓心脉宁片、银花泌炎灵片等。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":109.6,"timestamp":1732259013000,"preClose":113.01,"halted":0,"volume":6626999,"delay":0,"floatShares":398000000,"shares":401999999,"eps":9.2196,"marketStatus":"已收盘","marketStatusCode":5,"change":-3.41,"latestTime":"11-22 15:00:00","open":113,"high":113.1,"low":109.6,"amount":736000000,"amplitude":0.031,"askPrice":109.6,"askSize":21,"bidPrice":109.59,"bidSize":4,"shortable":0,"etf":0,"ttmEps":9.2196,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":113.01,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":124.31,"lowLimit":101.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":402290989,"pbRate":1.98,"roa":"--","roe":"12.43%","epsLYR":11.21,"committee":-0.531915,"marketValue":44091000000,"floatMarketCap":43632000000,"peRate":11.887718,"changeRate":-0.0302,"turnoverRate":0.0166,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。"},"requestUrl":"/m/hq/s/000661/tweets","defaultTab":"tweets","newsList":[{"id":"2485436282","title":"国金证券：给予长春高新买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2485436282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485436282?lang=zh_cn&edition=full","pubTime":"2024-11-21 14:10","pubTimestamp":1732169437,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维近期对长春高新进行研究并发布了研究报告《发布拟回购股份公告，彰显长期发展信心》，本报告对长春高新给出买入评级，当前股价为112.62元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为138.48。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100017665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"gpt_icon":0},{"id":"2484690668","title":"《股市简讯》中国长春高新一度劲扬5.6%，拟以3-5亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2484690668","media":"路透中文","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484690668?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:00","pubTimestamp":1731909653,"startTime":"0","endTime":"0","summary":"《股市简讯》中国长春高新一度劲扬5.6%，拟以3-5亿元回购公司股份* 中国生长激素生产商--长春高新000661.SZ周一盘中一度升5.6%，稍早称拟以3-5亿元回购公司股份。* 中证医药100指数.CSI000978跌0.8%。* 长春高新公告称，拟以3-5亿元回购公司股份，回购价格不超过160.00元/股。（完）\n 更多股市简讯请点选CN-CMN-HOT (发稿 宿泱韫; 审校 林高丽) ((jenny.su@thomsonreuters.com; 86-10-56692102;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP0DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0046","BK0057","BK0075","000661","BK0188","BK0239"],"gpt_icon":0},{"id":"2483849378","title":"长春高新最新公告：拟3亿元-5亿元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2483849378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483849378?lang=zh_cn&edition=full","pubTime":"2024-11-15 20:40","pubTimestamp":1731674452,"startTime":"0","endTime":"0","summary":"长春高新公告，公司拟使用自有资金及金融机构股票回购专项贷款资金3亿元-5亿元回购股份，全部用于后续实施公司及子公司核心团队股权激励或员工持股计划。回购价格不超过160.00元/股。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500040160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0075","BK0188","BK0057","BK0028","BK0239"],"gpt_icon":0},{"id":"2483320150","title":"长春高新(000661.SZ)拟回购3亿元至5亿元公司股份 已获3.5亿元回购贷款承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2483320150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483320150?lang=zh_cn&edition=full","pubTime":"2024-11-15 20:38","pubTimestamp":1731674298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，公司拟使用自有资金及金融机构股票回购专项贷款资金，以集中竞价交易方式回购部分公司已在境内发行的人民币普通股(A股)股票，全部用于后续实施公司及子公司核心团队股权激励或员工持股计划。本次拟回购资金总额不低于3亿元(含)、不超过5亿元(含)，回购价格不超过160元/股。截至公告披露日，公司已经取得了平安银行股份有限公司长春分行出具的《贷款承诺函》，同意为公司实施股票回购提供专项贷款项目提供金额3.5亿元、业务期限1年的贷款支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0239","BK0057","BK0028","BK0188","000661","BK0075"],"gpt_icon":0},{"id":"2483203143","title":"长春高新：拟3亿元-5亿元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2483203143","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483203143?lang=zh_cn&edition=full","pubTime":"2024-11-15 20:35","pubTimestamp":1731674132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0046","BK0239","BK4211","FISI","BK0057","BK0028","BK0188","000661","BK0075"],"gpt_icon":0},{"id":"2482794339","title":"长春高新三季报“变脸”：生长激素市场增长放缓，多领域子公司业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2482794339","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482794339?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:04","pubTimestamp":1731373440,"startTime":"0","endTime":"0","summary":"财报显示，长春高新的核心子公司——长春金赛药业有限责任公司的生长激素产品销售增长明显放缓，尤其是长效生长激素“金赛增”在遭遇新竞品涌现和集采政策双重夹击下，销售压力倍增。子公司百克生物因带状疱疹减毒活疫苗销量减少，导致收入及净利润双降；而高新地产则受房地产市场低迷影响，业绩表现同样不佳。这些业务的承压，进一步加剧了长春高新整体业绩的下滑趋势。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-11-12/doc-incvuhuh8452154.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-11-12/doc-incvuhuh8452154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0239","BK0057","BK0028","BK0188","000661","BK0075"],"gpt_icon":0},{"id":"2481452099","title":"长春高新最新公告：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2481452099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481452099?lang=zh_cn&edition=full","pubTime":"2024-11-05 18:01","pubTimestamp":1730800891,"startTime":"0","endTime":"0","summary":"长春高新公告称，公司子公司金赛药业的聚乙二醇重组人生长激素注射液（商品名：金赛增）新适应症上市申请已获国家药监局批准，用于特发性身材矮小（ISS）治疗。该药品是全球首个获批此适应症的长效生长激素，规格为27IU/4.5mg/0.5ml/瓶。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500030912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0075","000661","BK0188","BK0239","BK0057","BK0028"],"gpt_icon":0},{"id":"2481520631","title":"长春高新(000661.SZ)：聚乙二醇重组人生长激素注射液新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2481520631","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481520631?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:55","pubTimestamp":1730800516,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司长春金赛药业有限责任公司(简称“金赛药业”)聚乙二醇重组人生长激素注射液(简称“长效生长激素”)新适应症(用于特发性身材矮小(ISS))上市申请获得国家药品监督管理局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0188","BK0057","BK0239","BK0028","BK0075","BK0046"],"gpt_icon":0},{"id":"2481527986","title":"长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2481527986","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481527986?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:51","pubTimestamp":1730800272,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","000661","BK0057","BK1141","03347","BK0028","BK0188","BK1576","BK0046","BK0239","BK0075"],"gpt_icon":0},{"id":"2480346998","title":"国泰大健康风格漂移引质疑：基金经理徐治彪曾高位买入长春高新和老百姓","url":"https://stock-news.laohu8.com/highlight/detail?id=2480346998","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480346998?lang=zh_cn&edition=full","pubTime":"2024-11-04 10:38","pubTimestamp":1730687880,"startTime":"0","endTime":"0","summary":" 自9月下旬一揽子增量利好政策密集发布以来，A股市场持续走高，风险偏好提升，市场交易显著回暖。国泰基金权益投资部总监徐治彪认为，其本质是估值极度压缩、政策转向带来风险偏好提升。 徐治彪表示，市场波动率显著上升，趋势资金主导市场情绪，市场容易出现阶段性单边大幅波动。2017年10月起任国泰大健康股票型证券投资基金的基金经理。 基金业绩下降，自然会对基金规模也造成影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/fund/jjzl/2024-11-04/doc-incuwfyi5612701.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjzl/2024-11-04/doc-incuwfyi5612701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0057","BK0188","BK0239","BK0028","603883","BK0075","BK0046","BK0209","000661"],"gpt_icon":0},{"id":"2479982844","title":"【机构调研记录】鑫元基金调研长春高新、澳华内镜等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479982844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479982844?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:05","pubTimestamp":1730160337,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月28日披露的机构调研信息，鑫元基金近期对6家上市公司进行了调研，相关名单如下：1）长春高新 个股亮点：国内生长激素行业龙头；公司艾塞那肽产品；子公司金赛药业为重组生长激素国内基因重组蛋白药物龙头；创新药伪人参皂苷GQ处于临床2期，艾塞那肽申报待批。旗下最近一年表现最佳的公募基金产品为鑫元数字经济混合发起式A，最新单位净值为1.13，近一年增长22.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0028","BK0251","688212","BK0188","BK0057","BK0239","000661","BK0046"],"gpt_icon":0},{"id":"2479404498","title":"【机构调研记录】诺安基金调研博腾股份、长春高新等10只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479404498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479404498?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:05","pubTimestamp":1730160331,"startTime":"0","endTime":"0","summary":"；公司基因细胞治疗CDMO服务主要由二级控股子公司苏州博腾承接2）长春高新 个股亮点：国内生长激素行业龙头；公司艾塞那肽产品；子公司金赛药业为重组生长激素国内基因重组蛋白药物龙头；创新药伪人参皂苷GQ处于临床2期，艾塞那肽申报待批。4）新相微 个股亮点：公司主营显示芯片的研发、设计、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","300363","BK0239","BK0075","BK0188","BK0057","BK0046","BK0028"],"gpt_icon":0},{"id":"2479649824","title":"【机构调研记录】泰信基金调研长春高新、龙迅股份等7只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479649824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479649824?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:04","pubTimestamp":1730160291,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月28日披露的机构调研信息，泰信基金近期对7家上市公司进行了调研，相关名单如下：1）长春高新 个股亮点：国内生长激素行业龙头；公司艾塞那肽产品；子公司金赛药业为重组生长激素国内基因重组蛋白药物龙头；创新药伪人参皂苷GQ处于临床2期，艾塞那肽申报待批。2）龙迅股份 个股亮点：公司高速混合信号芯片产品主要可分为高清视频桥接及处理芯片与高速信号传输芯片。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0057","BK0075","BK0231","000661","BK0188","BK0239","688486","BK0214"],"gpt_icon":0},{"id":"2478487482","title":"长春高新：会积极关注并购重组等多种工具方式 提升上市公司投资价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2478487482","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478487482?lang=zh_cn&edition=full","pubTime":"2024-10-28 22:51","pubTimestamp":1730127112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0057","000661","BK0188","BK0046","161123","BK0239","BK0075","BK0028"],"gpt_icon":0},{"id":"2478889175","title":"长春高新：10月27日接受机构调研，北京成泉资本、东方财富等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2478889175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478889175?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:25","pubTimestamp":1730103942,"startTime":"0","endTime":"0","summary":"报告期内，公司核心子公司金赛药业经营情况平稳，实现收入 81.63 亿元，同比增长 0.55%；实现归属母公司所有者的净利润 28.39 亿元，同比下降 19.45%。前三季度，销售费用 31.44 亿元，同比增长 11.70%。管理费用 8.38 亿元，同比增长 48.18%，原因仍为金赛药业新 BU 管理架构的调整及子公司的设立、部分销售人员职责变化。同时公司抓住契机，积极申请国家医保目录准入。长春高新主营业务：生物制药及中成药的研发、生产和销售,辅以房地产开发、物业管理和服务等业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800020229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0326950275.SGD","BK0188","BK0201","BK0276","300059","BK0028","BK0046","SG9999014674.SGD","LU1997245177.USD","BK0057","BK0077","BK0239","BK0055","BK0075","LU2580892862.HKD","LU1997245094.SGD","LU2580892789.USD","BK0095","000661","BK0196"],"gpt_icon":0},{"id":"2478738351","title":"10月28日长春高新涨7.55%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2478738351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478738351?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:20","pubTimestamp":1730103659,"startTime":"0","endTime":"0","summary":"证券之星消息，10月28日长春高新涨7.55%，收盘报111.59元，换手率4.18%，成交量16.64万手，成交额18.08亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共72家，其中持有数量最多的公募基金为招商国证生物医药指数C。招商国证生物医药指数C目前规模为21.69亿元，最新净值0.4115，较上一交易日上涨2.24%，近一年下跌13.95%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800020029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0046","BK0188","000661","BK0239","BK0057","161726","BK0028","399441"],"gpt_icon":0},{"id":"2478178032","title":"长春高新涨7.55%，国金证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478178032","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478178032?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:20","pubTimestamp":1730103653,"startTime":"0","endTime":"0","summary":"今日长春高新涨7.55%，收盘报111.59元。2024年8月16日，国金证券研究员袁维发布了对长春高新的研报《费用端短期承压，产品布局持续深化》，该研报对长春高新给出“买入”评级。维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为西南证券的马云涛。长春高新个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800020026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"gpt_icon":0},{"id":"2478186191","title":"中国银河：给予长春高新买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478186191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478186191?lang=zh_cn&edition=full","pubTime":"2024-10-27 09:55","pubTimestamp":1729994116,"startTime":"0","endTime":"0","summary":"中国银河证券股份有限公司程培,宋丽莹近期对长春高新进行研究并发布了研究报告《2024年三季报业绩点评：金赛药业营收企稳，转型持续推进》，本报告对长春高新给出买入评级，当前股价为103.76元。 金赛药业营收持平企稳，利润受研发费用影响。24Q3营收下滑主要由于带状疱疹减毒活疫苗销量减少。最新盈利预测明细如下：该股最近90天内共有9家机构给出评级，买入评级8家，增持评级1家；过去90天内机构目标均价为142.54。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700009548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601881","000661"],"gpt_icon":0},{"id":"2478922742","title":"子公司金赛药业、百克生物业绩下滑，长春高新前三季度净利降两成","url":"https://stock-news.laohu8.com/highlight/detail?id=2478922742","media":"新京报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478922742?lang=zh_cn&edition=full","pubTime":"2024-10-26 21:46","pubTimestamp":1729950360,"startTime":"0","endTime":"0","summary":"新京报讯 10月26日，长春高新发布2024年第三季度报告。对于业绩变动的原因，长春高新表示，2024年前三季度，公司实现营业收入103.88亿元，同比下降2.75%；实现归属于上市公司股东净利润27.89亿元，同比下降22.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241026214855a1ed0c58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241026214855a1ed0c58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0046","BK0239","000661","BK0057","BK0075","BK0188","BK0028","688276"],"gpt_icon":0},{"id":"2478195157","title":"图解长春高新三季报：第三季度单季净利润同比减26.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478195157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478195157?lang=zh_cn&edition=full","pubTime":"2024-10-26 00:49","pubTimestamp":1729874980,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新2024年三季报显示，公司主营收入103.88亿元，同比下降2.75%；归母净利润27.89亿元，同比下降22.8%；扣非净利润28.41亿元，同比下降21.45%；其中2024年第三季度，公司单季度主营收入37.49亿元，同比下降16.94%；单季度归母净利润10.69亿元，同比下降26.37%；单季度扣非净利润11.03亿元，同比下降24.02%；负债率16.28%，投资收益-1.14亿元，财务费用-7379.08万元，毛利率85.6%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600000571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","stockEarnings":[{"period":"1week","weight":-0.0064},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.3771},{"period":"6month","weight":-0.0231},{"period":"1year","weight":-0.2728},{"period":"ytd","weight":-0.2193}],"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","perCapita":"2995股","boardName":"医药制造业","registeredCapital":"40229万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 长春高新技术产业(集团)股份有限公司的主营业务为生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品为聚乙二醇重组人生长激素注射液、重组人生长激素、注射用重组人促卵泡激素、冻干水痘减毒活疫苗、人用狂犬病疫苗、血栓心脉宁片、银花泌炎灵片等。","serverTime":1732297506573,"listedPrice":8.8,"stockholders":"132885人(较上一季度减少2.16%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}